Articles related to CLINICAL TRIALS

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.

In a recent phase 3 trial, asciminib has shown superior efficacy and safety in newly diagnosed chronic myeloid leukemia patients, achieving a higher major molecular response rate at week 48 compared to traditional tyrosine kinase inhibitors.

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.

Semaglutide has been shown to reduce the risk of major kidney disease events and cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

The phase 3 trial of aficamten for symptomatic obstructive hypertrophic cardiomyopathy showed a significant improvement in peak oxygen uptake compared to placebo, with meaningful enhancements in patient-reported outcomes and clinical measures.